Cargando…
Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
BACKGROUND: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. METHODS: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645737/ https://www.ncbi.nlm.nih.gov/pubmed/36352356 http://dx.doi.org/10.1186/s12879-022-07808-2 |
_version_ | 1784827018477568000 |
---|---|
author | Xu, Chuancai He, Zhisong Lei, Wei Chen, Li Shen, Dan Wang, Xiaofei Xu, Deyu Xu, Ying Huang, Jian’an |
author_facet | Xu, Chuancai He, Zhisong Lei, Wei Chen, Li Shen, Dan Wang, Xiaofei Xu, Deyu Xu, Ying Huang, Jian’an |
author_sort | Xu, Chuancai |
collection | PubMed |
description | BACKGROUND: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. METHODS: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People’s Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients. RESULTS: The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5–14] days) and PV (13 [IQR, 9–16.75] days) groups than in the UV group (15 [IQR, 11.75–17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08–63.59] and 0.3 S/co [IQR, 0.05–2.29], respectively) and PV (0.68 S/co [IQR, 0.14–28.69] and 0.12 S/co [0.03–5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03–0.47] and 0.04 S/co [IQR, 0.02–0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively). CONCLUSIONS: Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07808-2. |
format | Online Article Text |
id | pubmed-9645737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96457372022-11-14 Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study Xu, Chuancai He, Zhisong Lei, Wei Chen, Li Shen, Dan Wang, Xiaofei Xu, Deyu Xu, Ying Huang, Jian’an BMC Infect Dis Research BACKGROUND: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. METHODS: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People’s Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients. RESULTS: The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5–14] days) and PV (13 [IQR, 9–16.75] days) groups than in the UV group (15 [IQR, 11.75–17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08–63.59] and 0.3 S/co [IQR, 0.05–2.29], respectively) and PV (0.68 S/co [IQR, 0.14–28.69] and 0.12 S/co [0.03–5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03–0.47] and 0.04 S/co [IQR, 0.02–0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively). CONCLUSIONS: Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07808-2. BioMed Central 2022-11-09 /pmc/articles/PMC9645737/ /pubmed/36352356 http://dx.doi.org/10.1186/s12879-022-07808-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Xu, Chuancai He, Zhisong Lei, Wei Chen, Li Shen, Dan Wang, Xiaofei Xu, Deyu Xu, Ying Huang, Jian’an Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study |
title | Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study |
title_full | Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study |
title_fullStr | Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study |
title_full_unstemmed | Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study |
title_short | Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study |
title_sort | comparison of the duration of viral rna shedding and anti-sars-cov-2 spike igg and igm antibody titers in covid-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645737/ https://www.ncbi.nlm.nih.gov/pubmed/36352356 http://dx.doi.org/10.1186/s12879-022-07808-2 |
work_keys_str_mv | AT xuchuancai comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT hezhisong comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT leiwei comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT chenli comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT shendan comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT wangxiaofei comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT xudeyu comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT xuying comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy AT huangjianan comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy |